Genetic programming may replace a lifetime of medicine, but there is a catch

Imagine getting a single treatment that could keep your cholesterol under control for decades, potentially eliminating the need for daily medications. Advances in genetic engineering are bringing that reality closer. But scientists say the same technology that could revolutionize medicine also raises serious questions about safety, permanent genetic changes, and unintended consequences.
Gene therapy is already being used to treat certain serious diseases. These therapies can introduce functional copies of genes, silence harmful gene activity, or make changes directly to DNA. Unlike conventional drugs that must be taken repeatedly, some gene therapies are designed to work after just one administration.
More than 6,000 rare genetic diseases have been identified, although only a small proportion currently have curable targets. Gene therapies have already achieved significant success against conditions such as spinal muscular atrophy and sickle cell disease.
Now, researchers are testing whether the same methods can help prevent or treat more widespread health problems, including high cholesterol, heart disease, obesity and diabetes.
That raises an important question: Just because scientists can permanently change the function of a person’s genes, does that mean they should?
According to an opinion published in JAMA Internal MedicineUniversity of Michigan Health Frankel Cardiovascular Center Cardiologists Eric D. Smith, MD, and Venkatesh L. Murthy, MD, Ph.D., explain how doctors and researchers should weigh the potential benefits of genomic therapies against their risks.
Two gene therapy researchers explain why these therapies are so promising, what makes them different from conventional medicine, and what needs to happen before they can be safely given to millions of people.
Why One-Time Gene Therapy Is Different From Everyday Medicine
One of the most attractive features of gene therapy is the possibility of permanent results without repeated treatments.
Traditional medicine usually only works as long as patients continue to take it. Genomic therapies work differently because they work on the genetic material itself. They may provide a healthy version of a gene, suppress a gene responsible for harmful effects, or change a specific DNA sequence.
This makes it possible to develop a treatment that aims to work after a single dose. Such treatments are often called “one-and-done treatments”.
However, receiving treatment only once does not mean that its effects will last a lifetime.
Smith explains that many gene therapies use modified bacteria to deliver genetic instructions to cells. The immune system can recognize these vehicles and mount a response against them. As a result, providing the same treatment again may be difficult or impossible, even if your benefits start to fade.
Another important difference concerns which cells are replaced. Current gene therapies generally target somatic cells, which are cells of the body other than those involved in reproduction. Unlike germline editing, this treatment is not intended to create genetic changes that can be inherited by future generations.
Why Programming Common Genetic Diseases Raises New Risks
For people living with rare, damaging genetic conditions, the benefits of gene therapy may outweigh the potential risks. Some patients have few viable treatment options, making even experimental interventions worth considering.
The situation becomes more complicated when the same technology is used against common diseases.
Conditions such as high cholesterol, heart disease, obesity, and diabetes already have established treatments. Many of these medications can be adjusted as the patient’s condition changes or discontinued if severe side effects occur.
Permanent genetic interventions may not provide that flexibility.
Murthy also points to a major concern involving the number of people who may receive this treatment. A rare serious side effect can still harm a large number of patients if the treatment is given to millions.
For that reason, treatments intended for widespread use must meet the most demanding safety standards.
Five Questions Scientists Say Should Be Answered
To help determine when genomic therapy is appropriate, Smith and Murthy propose evaluating five key factors:
- Severity of disease: How serious is the condition being treated, and how much can patients benefit?
- Available treatments: Are there already effective treatments that can be modified or discontinued if needed?
- Treatment intensity: Is the target tissue suitable for interventions aimed at producing lasting results after a single dose?
- Delivery risk: Are the potential risks associated with delivering gene therapy reasonable given the severity of the disease?
- Long term monitoring: Can researchers reliably track safety and efficacy over many years, especially when large numbers of people receive the treatment?
The last question may be especially challenging.
Clinical trials usually involve small groups of patients who are monitored for a limited period of time. Although these studies can identify many safety concerns, they may miss very rare problems or problems that take years to develop.
Some side effects may only become apparent after the treatment has reached too many people.
The Problem of Tracking Accidents That May Appear Years Later
Smith says long-term monitoring cannot be considered an afterthought. It needs to be an integral part of how gene therapies are incorporated into medical practice.
Patient registries, which collect information about people receiving certain treatments, have already shown how important extended follow-up can be.
However, treatments that could eventually reach millions of patients will require surveillance systems that can operate on a much larger scale.
These programs should be independent and consistent so that researchers can consistently assess whether treatment remains effective and whether unexpected health problems develop over time.
Without reliable long-term information, doctors may struggle to determine the full effects of genetic interventions that are not easily reversible.
Could Some Genetic Changes Be Too Dangerous to Be Made Permanently?
Another concern is whether certain diseases or biological processes are amenable to permanent treatment.
Murthy emphasizes that developing the ability to modify genes does not automatically make doing so the best medical decision.
Some conditions require careful adjustments in medication dosages over time. In some cases, the difference between effective and harmful treatment can be very small. Changing a biological process too much or too little can cause serious problems.
Conventional medicine offers a significant advantage in these conditions because doctors can change or stop treatment as needed.
Permanent genetic therapies usually do not have that option.
Scientists may eventually overcome this limitation by developing gene therapy that “does not alter” the built-in biology or other ways to reverse its effects.
Until such methods are shown to work reliably, the ability to delay or modify treatment remains an important safety advantage of traditional medicine.
The Million-Dollar Challenge Facing Gene Therapy
Safety is not the only barrier to bringing gene editing into mainstream healthcare. Cost can also determine whether these treatments are widely available.
Some existing gene therapies have a price tag of more than $1 million for a single patient, and several cost much more.
Such amounts may be considered appropriate for certain rare, life-threatening conditions, especially where treatment options are very limited.
But applying the same rates to diseases that affect millions of people will put enormous financial pressure on health care systems.
Smith and Murthy argue that affordability and access should be part of the conversation from the start.
Even the most successful gene therapy can create new health care inequities if only a small percentage of patients can get it. Researchers and policy makers must consider not only whether these treatments work, but whether they can be delivered without worsening existing disparities.
Can One Gene Editing Therapy Prevent Heart Disease for Decades?
Despite these challenges, the opportunity to use gene editing to prevent common diseases is increasingly becoming a reality.
Researchers are already conducting early studies to investigate whether a single gene therapy can produce long-lasting reductions in LDL, commonly known as “bad,” cholesterol.
LDL cholesterol contributes to the buildup of fat inside the blood vessels, which can increase the risk of heart attacks and other heart problems. Lowering LDL in the long term is an important strategy for reducing cardiovascular risk.
If gene editing can safely produce sustained reductions, it could eventually provide a new way to protect cardiovascular health without requiring patients to take drugs forever.
However, promising early results may not be enough to justify widespread use.
Before these treatments become common options in routine cases, researchers will need convincing evidence that their benefits are permanent, their risks remain acceptably low over many years, and their costs are manageable. Reliable defenses will also be important.
For Smith and Murthy, the goal is not to withhold genetic medicine. It is to ensure that technologies that have the potential to transform healthcare are introduced carefully and responsibly.
As gene therapy moves beyond rare disorders to conditions affecting millions of people, a key challenge will be to ensure that the promise of lasting protection does not come at the expense of long-term patient safety.
Source link

